U.S., Feb. 25 -- ClinicalTrials.gov registry received information related to the study (NCT06842355) titled 'A Study of TYRA-300 in Children With Achondroplasia: BEACH301' on Jan. 29.
Brief Summary: The purpose of this study is to evaluate the safety, tolerability, and identify potentially effective dose(s) of TYRA-300 in children with achondroplasia with open growth plates.
Study Start Date: March, 2025
Study Type: INTERVENTIONAL
Condition:
Achondroplasia
Intervention:
DRUG: TYRA-300 0.125 mg/kg
Initial dose level of TYRA-300 per protocol, subsequent dose level escalations will occur based on criteria outlined in the protocol.
DRUG: TYRA-300 0.25 mg/kg
Subsequent dose level escalations will occur based on criteria outlined in the...